New survey of FDA AdCom members sets scene for potential reforms

A survey reflecting the opinions of more than 400 current and former US Food and Drug Administration (FDA) advisory committee members about issues impacting FDA Advisory Committee meetings, was submitted to the FDA docket today.

3D Communications, a communications consultancy with clients who appear before FDA Advisory Committees, conducted the survey over July 11-23, 2024.

The survey summarized 10 key recommendations generated from comments and suggestions of participants made during the FDA’s public meeting held on June 13, 2024, or that were posted to the public docket. The FDA described the meeting as a listening session “to solicit feedback on the Agency’s use of and processes for its advisory committee system.”